JointHealth™ express May 16, 2006
The New Brunswick Prescription Drug Program recently added etanercept (Enbrel®) to its coverage plan for juvenile rheumatoid arthritis (JRA) and psoriatic arthritis (PsA).
Juvenile Rheumatoid Arthritis
To qualify for coverage, one must meet the following criteria:
To qualify for coverage, one must meet the following criteria:
The New Brunswick Prescription Drug Program recently added etanercept (Enbrel®) to its coverage plan for juvenile rheumatoid arthritis (JRA) and psoriatic arthritis (PsA).
Juvenile Rheumatoid Arthritis
To qualify for coverage, one must meet the following criteria:
- Have moderate to severely active polyarticular juvenile rheumatoid arthritis (children between the ages of 4-17 years)
- Have not responded to adequate treatment with one or more disease modifying anti-rheumatic drugs (DMARDs) for at least three months OR have an intolerance to DMARDs
- Etanercept must be prescribed by a rheumatologist.
To qualify for coverage, one must meet the following criteria:
- Have active psoriatic arthritis
- Have not responded to an adequate trial with two disease modifying antirheumatic drugs (DMARDs) OR have an intolerance or contraindication to DMARDs
- Etanercept must be prescribed by a rheumatologist.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.